Brodalumab Drug Asset Due Diligence Report 2026

This Brodalumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Brodalumab can convert its Monoclonal antibody profile and IL-17RA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Brodalumab (query alias: brodalumab)
Modality / target	Monoclonal antibody; IL-17RA; IL-17RA antagonists
Highest global status	Approved
Originator	Amgen, Inc.
Active developers	LEO Pharma A/S, Bausch Health Cos., Inc., Kyowa Kirin Co., Ltd.

The MCP disease footprint includes Pustulosis of Palms and Soles, Ankylosing Spondylitis, Spondylarthritis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
EUCTR2021-003785-13-SE	Phase 4	Ongoing	15	Differentially expressed genes in lesional epidermis at baseline and week 12.
ISRCTN15271834	Phase 2	Ongoing	20	Not disclosed
NCT06673329	Phase 1	Recruiting	11	Number of Adverse Events

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Brodalumab Delivers 8 Years of Safety Success

Not Applicable; n=5654; evaluation: Positive. Reported fields: AE = 2.58 per 100 patients

Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial

Phase 3; n=126; evaluation: Positive. Reported fields: PPPASI(16-week) = 8.45 ( 5.76 - 11.13); PPPASI(16-week) = 13.73 ( 10.91 - 16.56)

A Phase 3, Randomised, Double-blind, Multi-centre Trial to Evaluate the Efficacy, Safety, and Tolerability of Brodalumab Treatment Compared to Placebo and Ustekinumab in Adolescent Subjects With Moderate-to-severe Plaque Psoriasis

Phase 3; n=12; evaluation: not stated. Reported fields: -; -; Psoriasis Area and Severity Index (PASI) 75 Response, Assessed at Week 12. = NA Participants

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Brodalumab addresses Pustulosis of Palms and Soles, Ankylosing Spondylitis, Spondylarthritis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-08-13	LEO Pharma to globally develop and commercialize Bausch Health's brodalumab for psoriasis, excluding Europe, US, and Canada.	Approved	Financial terms not disclosed
2016-07-01	AZ enters licensing agreements with LEO Pharma	Phase 3	US$115.0M upfront; US$1,000.0M milestones
2015-09-01	AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab	Phase 3	US$100.0M upfront; US$345.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of treating nonalcoholic fatty liver disease (NAFLD) using il-17ra antibody”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO